Cargando…
Understanding the burden of refractory myasthenia gravis
Myasthenia gravis (MG) is an autoantibody-mediated disease that compromises the acetylcholine receptors or associated structures of the postsynaptic membrane of the neuromuscular junction. This leads to impaired neuromuscular transmission and subsequent fluctuating fatigability and weakness of ocula...
Autores principales: | Schneider-Gold, Christiane, Hagenacker, Tim, Melzer, Nico, Ruck, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399761/ https://www.ncbi.nlm.nih.gov/pubmed/30854027 http://dx.doi.org/10.1177/1756286419832242 |
Ejemplares similares
-
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society
por: Melzer, Nico, et al.
Publicado: (2016) -
A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus
por: Schroeter, Michael, et al.
Publicado: (2021) -
Advances and challenges in the treatment of myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2021) -
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022) -
Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis
por: Harris, Linda, et al.
Publicado: (2019)